Can You Have Lyme Disease and Test Negative Despite Symptoms?
Lyme disease tests can be negative during early infection
Testing depends on the timing and development of antibodies
Symptoms, exposure history, and clinical judgment remain important
Many patients ask: Can you have Lyme disease and test negative despite continuing to experience symptoms?
Yes. A Lyme disease test can be negative, particularly when testing is performed early, before the immune system has produced a detectable antibody response.
Patients with Lyme disease symptoms may have negative or inconclusive laboratory results. This can be confusing, especially when symptoms persist and the test result does not appear to fit the clinical picture.
Lyme disease cannot always be evaluated through a single test result. Clinicians may need to consider the timing of testing, symptoms, exposure history, physical findings, previous treatment, and alternative diagnoses together.
Why Can a Lyme Disease Test Be Negative?
Most Lyme disease blood tests do not look directly for Borrelia burgdorferi, the principal bacterium responsible for Lyme disease in the United States. Instead, they measure antibodies produced by the immune system in response to the infection.
If testing is performed before enough antibodies have developed, the result may be negative even when the patient has Lyme disease. This period is sometimes called the diagnostic window.
False-negative antibody results are most clearly recognized during the first several weeks of infection. A negative result obtained months or years after symptoms began requires a broader clinical evaluation and should not automatically be attributed to the early testing window.
Factors that may contribute to a negative or inconclusive result include:
- Testing performed during the earliest stage of infection
- An antibody response that has not yet reached detectable levels
- Antibiotic treatment started before the antibody response fully developed
- Differences among tests, laboratories, and interpretive methods
- Symptoms caused by another tick-borne infection or an unrelated condition
Antibiotic treatment started during early infection may sometimes reduce or alter the subsequent antibody response. However, the degree to which this occurs varies and cannot be determined from a negative test alone.
How Standard Lyme Disease Testing Works
Standard Lyme disease antibody testing generally uses a two-step process. With conventional two-tier testing, the first step is an enzyme immunoassay. When the first result is positive or equivocal, a separate immunoblot is performed.
Modified two-tier testing uses two sequential enzyme immunoassays instead of an immunoblot as the second step. The U.S. Food and Drug Administration cleared modified two-tier testing for Lyme disease in 2019.3
The two-tier approach was adopted to standardize laboratory interpretation and improve specificity. It was not developed solely for public health surveillance.
Nevertheless, antibody testing is less sensitive during early infection. A patient with a characteristic erythema migrans rash may be diagnosed clinically because antibody tests can still be negative when the rash first appears.
Testing may become more informative when repeated several weeks later if early infection remains clinically suspected. Whether repeat testing is appropriate depends on the individual presentation and whether treatment has already begun.
What Does a Negative Lyme Test Mean?
A negative Lyme disease test reduces the likelihood of Lyme disease, but its meaning depends heavily on when the test was performed and why it was ordered.
A negative test obtained shortly after a tick bite or during the earliest symptoms may reflect testing before antibodies developed. By contrast, a negative result later in an untreated illness generally carries more diagnostic weight.
A negative test also does not evaluate for every infection transmitted by ticks. Babesiosis, anaplasmosis, ehrlichiosis, Borrelia miyamotoi disease, and other tick-borne illnesses require different testing.
Laboratory findings therefore need to be interpreted alongside the patient’s symptoms, exposure history, examination findings, and the timing of the illness.
Can Symptoms Continue Despite a Negative Lyme Test?
Yes. Symptoms can continue even when a Lyme disease test is negative, but a negative test does not establish why those symptoms are present.
Depending on the clinical circumstances, possible explanations may include:
- Early Lyme disease tested before antibodies developed
- Previous treatment before a full antibody response developed
- A tick-borne coinfection not detected by Lyme testing
- Persistent symptoms following previously treated Lyme disease
- Another infectious, inflammatory, neurologic, cardiac, endocrine, or rheumatologic condition
These possibilities cannot be distinguished by a Lyme antibody test alone. Persistent symptoms require an individualized assessment rather than an assumption that every negative result is either definitive or meaningless.
Early Infection Versus Symptoms Months or Years Later
The timing distinction is important. False-negative results are well documented during early localized Lyme disease, when the antibody response is still developing.
When symptoms have been present for months or years, the interpretation becomes more complex. A negative antibody test during a later untreated manifestation generally weighs against Lyme disease, although unusual seronegative cases have been reported.
Previous antibiotic treatment can complicate this interpretation. In addition, antibody tests cannot determine whether a past infection has resolved because antibodies may remain detectable long after treatment.
Therefore, neither a positive nor a negative antibody result can independently determine whether current symptoms represent active infection.
Physician Concerns About Seronegative Lyme Disease
Concerns about seronegative Lyme disease have existed for decades. In a 1996 survey of physicians practicing in Lyme-endemic regions, half believed that at least 25% of patients with Lyme disease could be seronegative.1
This survey reflected physician opinions and diagnostic experiences at that time. It did not directly measure the false-negative rate of current Lyme disease tests.
In a 1988 report, Dattwyler and colleagues described patients with clinical features of chronic Lyme disease who did not have detectable antibodies by the serologic methods used in that study. The investigators reported cellular immune responses to B. burgdorferi in these patients.2
These older findings remain part of the scientific discussion, but they should be interpreted in light of changes in test design, laboratory standardization, and diagnostic criteria.
Western Blot Bands and Their Interpretation
The Western blot, or immunoblot, detects antibodies directed against specific proteins associated with Borrelia burgdorferi. Results may display individual bands representing immune reactivity to different antigens.
The conventional criteria include the following bands:
- IgM: 23, 39, and 41 kDa
- IgG: 18, 23, 28, 30, 39, 41, 45, 58, 66, and 93 kDa
Under conventional criteria, an IgM immunoblot is considered positive when at least 2 of the 3 designated bands are present. An IgG immunoblot is considered positive when at least 5 of the 10 designated bands are present.
IgM immunoblot results are generally intended for patients whose symptoms began within the previous 30 days. Positive IgM findings later in an illness require particular caution because false-positive IgM reactions can occur.
Some laboratories also report reactivity to additional antigens, including bands at approximately 31 and 34 kDa. These bands are not included in the standard criteria used for conventional two-tier testing.
Individual bands can sometimes provide supporting information, but no single Western blot band establishes a Lyme disease diagnosis. Band patterns must be interpreted within the testing method, the performance characteristics of the laboratory, and the patient’s clinical presentation.
Some specialty laboratories report additional bands or apply interpretive criteria that differ from standard two-tier criteria. These results require cautious clinical interpretation because alternative criteria may not have the same degree of validation or specificity.
Surveillance Criteria and Clinical Diagnosis
Public health surveillance criteria are designed to classify and count cases consistently across populations. They are not intended to replace an individual clinical evaluation.
At the same time, standard laboratory criteria have an important role in reducing false-positive diagnoses. The distinction between surveillance and clinical diagnosis does not mean that any isolated band or nonstandard result confirms Lyme disease.
Clinicians must weigh the complete picture, including compatible signs and symptoms, geographic and tick exposure, the stage of illness, previous treatment, laboratory results, and reasonable alternative diagnoses.
Why Clinical Judgment Still Matters
Lyme disease may be diagnosed clinically in appropriate circumstances, particularly when a patient has a characteristic erythema migrans rash. Testing may not be necessary in that setting because early antibody results can be negative.
In presentations without a characteristic rash, testing usually becomes a more important part of the evaluation. However, laboratory testing supports diagnosis; it does not replace a careful history and physical examination.
This reflects the known limitations of Lyme disease testing, particularly during the early immune response.
Clinical judgment should also include consideration of diagnoses other than Lyme disease. This is especially important when symptoms are nonspecific or the exposure history is uncertain.
Can Lyme Tests Determine Whether Infection Has Resolved?
No. Antibody tests are not tests of cure and cannot reliably determine whether Borrelia burgdorferi remains active after treatment.
Some patients continue to have detectable IgM or IgG antibodies long after treatment. Other patients treated early may never develop a strongly detectable antibody response.
A positive result does not necessarily prove that current symptoms are caused by active infection. Likewise, a negative result does not, by itself, explain persistent symptoms or establish that an infection has resolved.
Advances in Lyme Disease Testing
Lyme disease diagnostic testing continues to evolve. Researchers are studying approaches intended to improve sensitivity during early infection and provide more direct evidence of infection.
These approaches include enhanced antibody assays, cellular immune-response tests, antigen detection, molecular methods such as polymerase chain reaction, and other direct-detection technologies.
Each method has potential advantages and limitations. PCR, for example, may be useful with certain clinical specimens but has limited sensitivity in blood and is not a stand-alone test for most presentations of Lyme disease.
No currently available test can independently answer every clinical question about early infection, previous exposure, persistent symptoms, or resolution following treatment.
Frequently Asked Questions
Can you have Lyme disease and test negative?
Yes. Lyme disease antibody tests may be negative during early infection before detectable antibodies develop. The meaning of a negative result depends on the timing of testing, the clinical presentation, previous treatment, and the type of test used.
Why are Lyme disease tests sometimes falsely negative?
False-negative results occur most often when testing is performed during the first several weeks of infection. Early treatment, differences in immune response, and limitations in test sensitivity may also affect results.
What does a negative Lyme disease test mean?
A negative test reduces the likelihood of Lyme disease but does not always rule out early infection. A negative result obtained later in an untreated illness generally carries more diagnostic weight and should prompt consideration of other explanations.
Can you test negative for Lyme disease and still have symptoms?
Yes. Symptoms may continue despite a negative Lyme test, but the test cannot determine the cause. The evaluation may include the timing of testing, tick exposure, previous treatment, coinfections, and other medical conditions.
What does a negative Lyme IgM test mean?
A negative IgM result does not rule out very early Lyme disease, and IgM becomes less useful as the illness progresses. The result should be interpreted according to the timing of symptoms and the complete two-tier testing pattern.
Will you always test positive after having Lyme disease?
No. Some patients treated early may not develop a strongly detectable antibody response. Other patients remain antibody-positive for months or years. Antibody testing cannot determine by itself whether an infection is currently active or has resolved.
Should a Lyme disease test be repeated?
Repeat antibody testing may be considered when an initial test was performed early and clinical suspicion remains. The decision depends on the timing of symptoms, physical findings, previous antibiotic treatment, and the clinician’s assessment.
Clinical Takeaway
The meaning of a negative Lyme disease test depends on when the test was performed, whether treatment had already begun, the clinical presentation, and the type of test used. Antibody tests also cannot determine whether an infection has resolved or whether persistent symptoms represent active infection.
Lyme disease diagnosis requires integrating the clinical presentation, exposure history, physical findings, timing of testing, and laboratory evidence rather than relying on a single result.
Related Articles
How Accurate Are Lyme Disease Tests?
Persistent Lyme Disease Overview
Post-Treatment Lyme Disease Syndrome
Lyme Disease Coinfections
References
- Ziska MH, Donta ST, Demarest FC. Physician preferences in the diagnosis and treatment of Lyme disease in the United States. Infection. 1996;24(2):182-186.
- Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med. 1988;319(22):1441-1446.
- U.S. Food and Drug Administration. FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses. FDA. 2019.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
